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DNA/histone methylationAberrant upregulation of NOTCH3 gene plays a critical role in cancer pathogenesis. However, the underlying
mechanisms are still unknown. We tested here the hypothesis that aberrant epigenetic modifications in the
NOTCH3 promoter region might account for its upregulation in cancer cells. We compared DNA and histone
methylation status of NOTCH3 promoter region in human normal blood cells and T cell acute lymphoblastic leu-
kemia (T-ALL) cell lines, differentially expressing NOTCH3. We found that histone methylation, rather than DNA
hypomethylation, contributes towards establishing an active chromatin status of NOTCH3 promoter in NOTCH3
overexpressing cancer cells.Wediscovered that the chromatin regulator protein BORIS/CTCFL plays an important
role in regulatingNOTCH3 gene expression.We observed that BORIS is present in T-ALL cell lines aswell as in cell
lines derived from several solid tumors overexpressing NOTCH3. Moreover, BORIS targets NOTCH3 promoter in
cancer cells and it is able to induce and to maintain a permissive/active chromatin conformation. Importantly,
the association between NOTCH3 overexpression and BORIS presence was confirmed in primary T-ALL samples
from patients at the onset of the disease. Overall, our results provide novel insights into the determinants of
NOTCH3 overexpression in cancer cells, by revealing a key role for BORIS as the main mediator of transcriptional
deregulation of NOTCH3.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The human neurogenic locus notch homolog protein 3 (NOTCH3)
gene encodes the third discovered mammalian member of an evolu-
tionary conserved family of transmembrane protein receptors (NOTCH
1–4). Notch receptors are strictly required for normal embryonic devel-
opment and for homeostasis of a variety of adult tissues by controlling
the balance between proliferation versus differentiation of stem and/
or progenitor cells [1,2].
A deregulated Notch pathway has been found to be involved in
the development of a wide variety of human tumors with either an
oncogenic or a tumor-suppressive role depending on the cancerolecular Medicine, Faculty of
iale Regina Elena 291, 00161
Cellular Biotechnologies and
niversity of Rome, Via Chieti 7,
epanti), caiafa@bce.uniroma1.ittype, tissue context and the member of the Notch receptor family ac-
tivated [3,4].
An oncogenic role of NOTCH3 pathwaywas identified in T cell acute
lymphoblastic leukemia (T-ALL), since constitutive expressionof the ac-
tivated intracellular domain of NOTCH3 (NOTCH3-IC) has been shown
to induce T-cell neoplasias in transgenic mice [5] and the overexpres-
sion of NOTCH3 in the vast majority of T-ALL validates this finding in
humans [6].
Aberrant NOTCH3 signaling has been also observed in several solid
tumors, where NOTCH3 activation favors cell proliferation, resistance
to apoptotic stimuli, metastatic capability and maintenance of stem
cell-like features [7].
Moreover, a correlation betweenNOTCH3 expression and poor prog-
nostic outcome has been described in primary tumors thus confirming
NOTCH3 involvement in cancer pathogenesis [8–10].
Molecular details of the genetic mechanisms (i.e. gene amplification,
chromosome translocation) causingNOTCH3 receptor activation aswell
as the consequent activation of signaling are emerging in the context of
specific tumors [11–15], while the causes of NOTCH3 gene overexpres-
sion in cancer cells remain poorly understood.
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of genes critical to the development and progression of cancer. The fact
that the transcription start site (TSS) of NOTCH3 localizes within a CpG
island prompted us to investigate a possible correlation between
NOTCH3 gene DNA methylation status and gene expression extending
the analysis to histone methylation.
We report here that the cancer testis antigen (CTA) BORIS/CTCFL
(Brother Of Regulator of Imprinted Sites)/CTCF-like protein), paralog
of the widely expressed chromatin insulator CTCF (CCCTC-binding
factor) [16,17], is involved in the epigenetic deregulation leading to
NOTCH3 upregulation in cancer cells. In particular, BORIS presence mir-
rors NOTCH3 overexpression specifically in T-ALL established cell lines
as well as in primary T-ALL human samples from patients at the onset
of the disease. Furthermore, BORIS binding to NOTCH3 promoter is
associatedwith histonemodifications typical of permissive/active chro-
matin conformation. Overall, our data highlight a key role played by
BORIS in the abnormal upregulation of NOTCH3 in cancer cells.
2. Results
2.1. NOTCH3 gene expression and promoter epigenetic profile in normal
blood cells and in T-ALL cell lines
Whether or not DNA methylation of the NOTCH3 promoter restricts
NOTCH3 expression was investigated.
NOTCH3mRNA level analysis was performed by real-time RT-PCR in
normal blood cells [peripheral blood mononuclear cells (PBMCs),
CD4+ and CD8+ T-lymphocytes] and in T-ALL cell lines differentially
expressing NOTCH3 (MOLT3 and SKW3). Fig. 1A shows that the
NOTCH3mRNA level varied significantly with over 500-fold difference
between the lowest and highest expressing cell types (MOLT3 vs.
CD8+ T-lymphocytes). High NOTCH3 mRNA levels were found in
MOLT3 cells, while barely detectable NOTCH3 expression characterized
SKW3 cells. Notably, low levels of NOTCH3 transcript were detected in
all normal blood cells.
The dependence of NOTCH3 expression on DNA methylation of its
promoter, colocalizing with a CpG island (Fig. 1B), was investigated by
bisulfite sequencing in CD4+ T- lymphocytes and in MOLT3 and
SKW3 T-ALL cells. Fig. 1C shows that NOTCH3 promoter was
hypermethylated only in SKW3 cell line characterized by barely detect-
able levels of mRNA expression, while it was unmethylated in NOTCH3
expressing MOLT3 cell line. Intriguingly, the association between pro-
moter methylation and gene expression cannot be extended to normal
blood cells, where NOTCH3was not expressed in spite of the absence of
promoter methylation.
The data above revealed that the silencing of NOTCH3 in normal
blood cells is independent of DNA methylation, thus suggesting the in-
volvement of other mechanism(s). In order to address this issue,
our attention was focused on epigenetic changes involving histone
methylation.
In fact, it is well known that histone H3 dimethylation and
trimethylation at residue K4 (H3K4me2 andH3K4me3)mark transcrip-
tional competent chromatin with H3K4me3 particularly enriched in
actively transcribed promoters, while histone H3 trimethylation at res-
idue K9 (H3K9me3) and trimethylation at residue K27 (H3K27me3)
mark constitutive and facultative heterochromatin, respectively.
By chromatin immunoprecipitation (ChIP) analysis, these modifica-
tions were used to investigate the chromatin conformation status of
NOTCH3 promoter in cells differentially expressing NOTCH3 (Fig. 1 D).
The presence of a high amount of H3K4me2 and H3K4me3 versus
H3K9me3 and H3K27me3 indicates an active chromatin status in
MOLT3 cells,while highH3K9me3 versusH3K4me2andH3K4me3 indi-
cates a non-permissive chromatin status in SWK3 cells. These results
match with data of RT-PCR and cytosine methylation levels, showing
that NOTCH3 is expressed in MOLT3 and silenced in SKW3 cells by con-
stitutive heterochromatization.As with respect to PBMCs, the NOTCH3 silencing could be explained
by both the lowH3K4me3 and high H3K27me3 amounts. However, this
condition does not depend on the heterochromatization as indicated by
the absence of H3K9me3, whose presence instead characterizes SKW3
cells, which do not express NOTCH3.
2.2. CTCF and BORIS differentially occupy NOTCH3 promoter in normal
blood cells and T-ALL cell lines
To search for potential trans-acting protein factors responsible for
epigenetic regulation of NOTCH3 gene expression, the Genomatix
MatInspector software was used [18,19]. The inspection of
about 2000 bp of the NOTCH3 5-prime sequence (transcript ID
ENST00000263388) revealed the presence of eight regions located
in the proximity of the TSS (from −391 to +259) which match
with the CTCF binding sequence (data not shown). Three of them ex-
hibited a high degree of similarity to CTCF binding sites with a qual-
ity rating above the algorithm defined cut off value of 0.8 (Fig. 2A,
sites 1, 2 and 3). Furthermore, same result was obtained by compar-
ing the same region with previously published 20-bp binding motifs
for CTCF [20] (Fig. 2B). This was also suggested by ChIP-seq data from
the ENCODE consortium accessed through the UCSC genome brows-
er (http://genome.ucsc.edu) [21–23] (Supplementary Fig. S1).
CTCF DNA-target sites could also be bound by CTCFL/BORIS, a CTCF-
paralog protein that may have epigenetic CTCF-antagonistic regulative
functions on CTCF binding regions of target genes [17,24–26].
To address whether CTCF and BORIS are both involved in the regula-
tion of NOTCH3 expression, transcript levels of CTCF and BORISwere an-
alyzed by RT-PCR in normal blood cells and T-ALL cell lines, to compare
their expression with that of NOTCH3 (Fig. 1A).
To detect all the 23 known mRNA variants of BORIS [27], its expres-
sion was analyzed by quantitative RT-PCR with two sets of primers
encompassing 1–2 and 3–4 exon boundaries, respectively.
CTCF transcript levels were relatively similar in both normal
blood cells and T-ALL cell lines, irrespectively of NOTCH3 expression
(Fig. 3A). In contrast BORIS expression appeared to be restricted to T-
ALL cell lines. However, the presence of BORIS transcript did not corre-
late with the expression of NOTCH3. Indeed, it appears to be expressed
by both SKW3 cells, which do not express NOTCH3, and MOLT3 cells
(Fig. 3B and C), which express NOTCH3 and show permissive,
unmethylated chromatin status of NOTCH3 promoter (Fig. 1C and D).
To correlate the observed epigenetic chromatin status of NOTCH3
promoter with the presence of CTCF and/or BORIS, chromatin immuno-
precipitation (ChIP) experimentswere carried out onMOLT3 and SKW3
T-ALL cells, in comparison with PBMCs.
As shown in Fig. 3D, the ChIP analysis revealed that CTCF binds to the
proximalNOTCH3 promoter fragment containing putative CTCF-binding
sites 1 and 2 in PBMCs andMOLT3 cells, while no CTCF binding was de-
tected in SKW3 cells. Concerning BORIS, the proteinwas associatedwith
the same region bound by CTCF in MOLT3 cells, which overexpress
NOTCH3. Conversely, BORIS binding was undetectable in both PBMCs
and SKW3, which do not express NOTCH3. This finally would suggest
that the binding of BORIS to the NOTCH3 promoter directly correlates
with the gene expression.
2.3. NOTCH3 expression correlates with the methylation status of its
promoter and with BORIS expression in normal and cancer cell lines
In order to extend the study of the possible direct correlation be-
tween NOTCH3 expression with the methylation status of its promoter,
NOTCH3 mRNA level analysis was firstly performed by real-time RT-
PCR in normal blood cells (PBMCs, CD4+ and CD8+ T-lymphocytes),
in immortalized normal human fibroblasts (BJ) and in cell lines derived
from several cancers, including T-ALL (MOLT3, SKW3and Jurkat), breast
cancer (MCF7, T47D, MDA-MB-231, MDA-MB-453), melanoma (M14,
MDA-MB-435), and colon carcinoma (HCT116, HCT15, HT29). Fig. 4A
Fig. 1.Differential expression and promoter epigenetic status ofNOTCH3 in normal blood cells and T-ALL cell lines. (A) Expression ofNOTCH3 transcript as detected by quantitative RT-PCR
in normal blood cells (CD4+, CD8+ T-lymphocytes and PBMCs,) and in T-ALL cell lines (MOLT3 and SKW3). GUSB transcript level was used as endogenous control. Relative levels were
calculated taking the transcriptional levels ofNOTCH3 in PBMCs as 1. Results are means± s.e.m. calculated from three experiments. (B) Schematic map of theNOTCH3 5′-region showing
the position of the PCRproduct analyzed in the assay. TSS indicates the transcriptional start site. Gray box: untranslated 5′-region; openbox: coding exon; black horizontal line: CpG island.
Numbers in brackets indicate the nucleotide positions relative to the ATG initiator codon. (C) DNAmethylation profiling ofNOTCH3 promoter as detected by bisulfite sequencing in CD4+
normal blood T-cells and in the leukemic cell lines MOLT3 and SKW3. Each circle represents a CpG dinucleotide. Open circle, unmethylated CpG; black circle, methylated CpG. X indicates
cytosine positionswhere the sequence was indefinable. (D) ChIP analysis ofNOTCH3 promoter region for histone H3modifications in PBMCs and in theMOLT3 and SKW3 T-ALL cell lines.
Immunoprecipitation was performed by using specific antibodies to dimethyl and trimethyl lysine 4 (H3K4me2 and H3K4me3) and to trimethyl lysine 27 and 9 (H3K27me3 and
H3K9me3). Normal IgG were used as negative control (IgG). Arrow indicates the expected position of the band. Diagram represents the NOTCH3 5′-region with the schematic illustration
of the location of the PCR product analyzed in the assay.
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Fig. 2. In silico prediction of CTCF-bindingmotifs in the NOTCH3 promoter region. (A) Schematic representation of the NOTCH3 5′-region with the three sites showing high degree of sim-
ilarity to CTCF binding sites as predicted by the Genomatix MatInspector software. TSS indicates the transcriptional start site. Gray box: untranslated 5′-region; open box: coding exon.
Numbers in brackets indicate the nucleotide positions relative to the ATG initiator codon. (B) Sequence alignment of the putative CTCF sites in the NOTCH3 promoter with the 20-bp
core motif of known human CTCF DNA binding sites. Highlighted bold text: NOTCH3 sequence. Matching nucleotides between NOTCH3 and CTCF target genes are highlighted in light
gray. Open box indicates nucleotide positions that have been found highly conserved between functional CTCF binding sites genome-wide [20].
816 M. Zampieri et al. / Biochimica et Biophysica Acta 1839 (2014) 813–825shows differential expression of NOTCH3mRNA levels in different types
of tumors, aswell as in immortalized and normal human fibroblasts (BJ)
and in embryonic kidney HEK293T cells. Normal blood cells are includ-
ed as NOTCH3 non-expressing normal cells.
Then the DNA methylation status of NOTCH3 promoter in different
cells was investigated by bisulfite PCR followed by restriction analysis
(COBRA).
After bisulfite modification and PCR amplification of theNOTCH3 pro-
moter region, the PCR product was digested with BstUI restriction en-
zyme specific to CGCG containing sequences (Fig. 4B). Therefore,
following bisulfite reaction, cleavage occurs selectively when target se-
quences are methylated. Fig.4C shows that NOTCH3 promoter was
hypermethylated only in cancer cell lines characterized by its low
mRNA expression (SKW3, HT29, HELA, M14 and MDA-MB-231), while
it was unmethylated in all NOTCH3-expressing T-ALL and cancer cell
lines and in embryonic HEK293T cells. Notably, normal blood cells and fi-
broblast cell lines do not express NOTCH3 in spite of the absence of pro-
moter methylation.
A parallel analysis was performed on the same cell lines in order to
assess the presence of BORIS and CTCF transcripts. The results have
shown that while CTCF is expressed at similar levels in all samples
(Supplementary Fig. S2), BORIS expression is restricted to cancer cell
lines (Fig. 4D and E), irrespective of NOTCH3 expression.
The results at mRNA levels were confirmed at the protein level by
Western blots (Supplementary Fig. S3).
2.4. BORIS positively regulates NOTCH3 transcription and activity
Together, the results reported above indicate that, while BORIS ex-
pression alone is not sufficient, the combination of unmethylated status
of NOTCH3 promoter and BORIS expression represents the necessary
condition for NOTCH3 expression in cancer cells and in embryonic
HEK293T cells.
Luciferase reporter assay was used to investigate whether and where
NOTCH3 promoter activity directly responds to BORIS. Plasmids contain-
ing the NOTCH3 full promoter or its proximal/distal regions (Fig. 5A)
were transfected into both BORIS-negative BJ and BORIS-positiveHEK293T cells. According to BORIS presence, theNOTCH3 promoter activ-
ity was significantly higher in HEK293T cells. To note, this was ascribable
to the proximal promoter which contains putative CTCF binding sites
(Fig. 5B). The activatory role played by BORIS on NOTCH3 promoter was
further confirmed by siRNA-mediated BORIS silencing in HEK293T cells
(Fig. 5C). Taken together, these results indicate that BORIS, by targeting
the proximal region of its promoter, is a positive regulator of NOTCH3.
To address in-depth themolecular mechanism bywhich BORIS is in-
volved inNOTCH3 upregulation, experiments of BORIS silencing/overex-
pression were performed in the BORIS-positive cell line HEK293T
showing unmethylated NOTCH3 promoter and NOTCH3 expression
(Fig. 4 and Fig. S3).
In agreement with data obtained in luciferase reporter assays
(Fig. 5C) the expression of the endogenous NOTCH3 depended on the
BORIS level. In fact, endogenous NOTCH3was downregulated or upreg-
ulated at both mRNA and protein levels following BORIS silencing or
overexpression, respectively (Fig. 6A and B).
ChIP analysis experiments allowed us to further study what occurs
on NOTCH3 promoter following the modification of the BORIS level.
As shown in Fig. 6C, the silencing of BORIS reduced the amount of pro-
tein bound onNOTCH3 promoter, while upregulated BORIS protein levels
increased BORIS binding. Notably, these binding modifications correlate
with changes in histonemethylation patterns: enhanced BORIS occupan-
cy was associated with an increased amount of H3K4me3, while BORIS
depletion changed chromatin status of NOTCH3 promoter towards non-
permissive chromatin configuration as indicated by the decrease of the
H3K4me3 and the introduction of H3K27me3.
Overall, these results show a direct relationship between BORIS
binding to NOTCH3 promoter, histone methylation status and the ex-
pression of NOTCH3. Furthermore, they indicate that the binding of
BORIS to NOTCH3 promoter was sufficient to maintain switched on its
transcription.
Consistent with these findings, exogenous BORIS enforced expression
was sufficient to allow NOTCH3 expression in BORIS-negative BJ normal
fibroblasts (Fig. 7A and B). Notably, NOTCH3 upregulation associated
with BORIS recruitment to NOTCH3 promoter and with changes of pro-
moter chromatin status towards permissive chromatin configuration as
Fig. 3. CTCF and BORIS differentially occupy NOTCH3 promoter in normal blood cells and T-ALL cell lines. (A) Expression of CTCF transcript as detected by quantitative RT-PCR in normal
blood cells (CD4+, CD8+ T-lymphocytes and PBMCs) and in T-ALL cell lines (MOLT3 and SKW3). GUSB transcript level was used as endogenous control. Relative levels were calculated
taking the transcriptional levels of CTCF in PBMCs as 1. (B and C) Expression of BORIS transcripts as detected by quantitative RT-PCR in normal blood cells (CD4+, CD8+ T-lymphocytes
and PBMCs,) and in T-ALL cell lines (MOLT3 and SKW3). Two sets of primers encompassing 1–2 (E1–E2) and 3–4 (E3–E4) exonswereused to detect all known isoforms of BORIS transcript.
GUSB transcript served as loading control of total RNA. Relative levels were calculated taking the transcriptional levels of BORIS in MOLT3 as 1. Results shown in A, B and C are means ±
s.e.m. calculated from three experiments. ND, not detectable. (D) In vivo binding of CTCF and BORIS on the 5′-region ofNOTCH3 as detected by ChIP assay in PBMCs and in the leukemic cell
linesMOLT3 and SKW3. Normal IgGwere used as negative ChIP control (IgG).W indicated the no-template PCR control. Diagram represents theNOTCH3 5′-regionwith the location of the
putative CTCF binding sites and the PCR products analyzed in the assay. Region b corresponds to the PCR amplicon indicated in Fig. 1D. TSS indicates the transcriptional start site. Gray box:
untranslated 5′-region; open box: coding exon. Numbers in brackets indicate the nucleotide positions relative to the ATG initiator codon.
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histone modifications (Fig. 7C).
To determine the functional relevance of the BORIS-dependent
NOTCH3 upregulation we next investigated whether this event could
initiate the NOTCH3 signaling in BJ cells. To this end, BORIS overexpres-
sion was combined with the treatment with a specific NOTCH3-
neutralizing antibody able to inhibit the receptor activity. To assess
the NOTCH3 signaling activity, the levels of NOTCH3-IC and of its target
geneHES1 [1,2] weremonitored.We observed that upon BORIS overex-
pression, the NOTCH3-IC accumulation associatedwith a significant up-
regulation of HES1 mRNA. The latter effect was clearly dependent on
NOTCH3 activity as indicated by the fact that it was almost completely
abrogated by the addition of the NOTCH3 neutralizing antibody
(Fig. 7E), which is also able to reduce the levels of NOTCH3-IC
(Fig. 7D). These results indicate that the NOTCH3 protein induced by
BORIS is functional.2.5. Co-expression of BORIS and NOTCH3 in T-ALL
Considering the association between BORIS expression and NOTCH3
upregulation observed in T-ALL cell lines, whether or not this observa-
tion could be extended to human primary T-ALL samples was verified.
ThemRNA levels ofNOTCH3 and BORISwere examined in eight cases
of T-ALL and compared with normal peripheral blood T lymphocytes
and with MOLT3 cells.COBRA assay was carried out in parallel in the same samples, to ver-
ify themethylation status of NOTCH3 promoter. As shown in Fig. 8A and
B, sustained levels of NOTCH3 mRNA expression were associated with
the unmethylated status of promoter in all analyzed T-ALL samples.
Notably, the samples also showed the presence of the BORIS transcript
(Fig. 8C and D), further supporting the hypothesis that aberrant expres-
sion of BORIS combined with the unmethylated status of NOTCH3 pro-
moter is the event responsible for NOTCH3 expression in cancer.3. Discussion
NOTCH3 upregulation is involved in the pathogenesis of and charac-
terizes T-ALL [6], although the causes of such an upregulation are poorly
known. Thus, themolecularmechanisms underlyingNOTCH3 transcrip-
tional deregulation in T-ALL cells have been here investigated focusing
on epigenetic events and transcriptional factors involved.
Our data firstly show thatNOTCH3 gene expression does not directly
correlate with the methylation of its promoter. In fact, while promoter
methylated status correlates with NOTCH3 expression in T-ALL cell
lines, being unmethylated in NOTCH3-expressing MOLT3 cells and
hypermethylated in NOTCH3-negative SKW3 cells, its unmethylated
statuswasnot found to be enough to allowNOTCH3 transcription in nor-
mal blood cells. Thisfinding indicates that the absence of cytosinemeth-
ylation is not the key factor involved in transcriptional upregulation of
NOTCH3 in T-ALL cell lines and human primary samples, thus suggesting
Fig. 4. Analysis of NOTCH3 expression and promoter methylation status and of BORIS expression in normal and cancer cell lines. (A) Expression of NOTCH3 transcript as detected by quantitative RT-PCR. Relative levels were calculated taking the
transcriptional levels of NOTCH3 in PBMCs as 1. GUSB transcript level was used as endogenous control. Histogram columns are labeled by the mean expression values calculated from three experiments. Error bars indicate ± s.e.m. (B) Schematic
map of the NOTCH3 5′-region showing the position of the PCR product analyzed in the COBRA assay. Arrows indicate the approximate position of BstUI sites. TSS indicates the transcriptional start site. Gray box: untranslated 5′-region; open box:
coding exon. Numbers in brackets indicate the nucleotide positions relative to the ATG initiator codon. (C) NOTCH3 promoter DNA methylation profiling as detected by COBRA assay. A 332-bp PCR fragment is cleaved by BstUI when methylation
is present in bisulfite-modified DNA. UNCUT and CUT indicate samples treated or not with the restriction enzyme. (D and E) Expression of BORIS transcript as detected by quantitative RT-PCR. Two sets of primers encompassing 1–2 (E1–E2) and
3–4 (E3–E4) exons were used to detect all known isoforms of BORIS transcript. Detection of GUSB transcript served as loading control of total RNA. Relative levels were calculated taking the transcriptional levels of BORIS in MOLT3 as 1. Histogram
columns are labeled by the mean expression values calculated from three experiments. Error bars indicate ± s.e.m.
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Fig. 5.BORIS stimulates the activity of proximalNOTCH3promoter. (A) Schematicmap of theNOTCH35′-region showing the regions analyzed in the luciferase reporter assays. Numbers in
brackets indicate the nucleotide position relative to the ATG initiator codon. (B) Luciferase reporter activity in BORIS-negative BJ and BORIS-positive HEK293T cells. Cells were transfected
with luciferase reporter plasmids containing the fragments of NOTCH3 5′-region indicated in A. Cells were also transfected with CMV-β-gal to control transfection efficiency. Results are
presented as ratio of luciferase/β-galactosidase relative units and represent the relative fold change compared with the activity of the full promoter construct measured in the BJ sample.
(C) Luciferase reporter activity aftermodulation of BORIS expression levels by siRNA silencing inHEK293T cells. Transfection of non-targeting siRNAs (siRNACT)was performed as control.
Cells were also transfected with CMV-β-gal to control transfection efficiency. Results are presented as ratio of luciferase/β-galactosidase relative units and represent the relative fold
change compared with controls. Results shown in B and C are means ± s.e.m. calculated from three experiments. *P b 0.05 compared with BJ (B) or controls (C) (Student's t test).
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regulation of NOTCH3 in T-ALL.
Additional detailswere provided by the analysis of histoneH3meth-
ylation,which is known to acts in a combinatorial fashion to specify dis-
tinct transcriptional chromatin conformation [28]. The DNA promoter
hypermethylation of NOTCH3-negative cancer cells (SKW3) associates
with the predominant presence of H3K9me3, which generally marks si-
lenced heterochromatin. Conversely, unmethylated promoter in
NOTCH3-positive T-ALL cells (MOLT3) and in normal blood cells
shows divergent histone H3 methylation profiles. In NOTCH3-positive
leukemia cells the higher presence of H3K4me3 versus H3K27me3
clearly indicate transcriptional permissive status of the promoter,
while the higher level of H3K27me3 versus H3K4me3 in normal blood
cells explains the silencing of NOTCH3 despite the unmethylated status
of promoter. Thus, different from DNAmethylation, H3 histonemethyl-
ation seems to discriminate between normal and leukemia cells.
The involvement of epigenetic factors in driving chromatin confor-
mation changes in the NOTCH3 locus was then investigated. Attention
was focused on CTCF [29–32] and BORIS/CTCFL [16,17] paralog proteins,
as binding sites for CTCF were identified on NOTCH3 promoter. BORIS is
very similar to CTCF in the 11-zinc-finger DNA-binding domain and,
sharing part of DNA target sequences with this protein, could compete
with it. Conversely, CTCF and BORIS diverge in the N-and C-terminal
ends, allowing interaction with distinct partners [17,24–26].
BORIS is a cancer testis antigen (CTA) as it is normally expressed in
testis but aberrantly expressed in several primary tumors and established
cancer cell lines [16,17,27,33–35]. Importantly, BORIS itself has a pivotal
role in the expression of other CTAs (e.g. MAGE-A1) [36–39] and of
some proto-oncogenes (e.g. hTERT) [40,41], generally repressed by CTCF.
Analysis of CTCF and BORIS expression shows that, while CTCF is
expressed in both normal blood cells and T-ALL cell lines, BORIS is spe-
cifically expressed in T-ALL and solid tumor-derived cell lines.
Moreover, ChIP assay, used to assess the binding of CTCF and BORIS
proteins to the 5′ region of theNOTCH3 gene, demonstrated that the oc-
cupancy of NOTCH3 promoter by CTCF and/or BORIS correlates with
NOTCH3 expression, promoter epigenetic status and BORIS expression.In BORIS-negative normal blood cells, the presence of repressive H3
modifications coincides with CTCF binding at proximal NOTCH3 pro-
moter. Conversely, in MOLT3 cells the binding of both CTCF and BORIS
correlates with an active chromatin status and upregulated NOTCH3 ex-
pression. To note, in SKW3 cells, characterized by NOTCH3 silencing,
neither CTCF nor BORIS are bound on the hypermethylated/heterochro-
matic promoter. These results show that NOTCH3 expression varies ac-
cording to the binding of BORIS rather than CTCF, and that this binding
depends, in turn, on promoter chromatin accessibility. This suggests
that both the unmethylated status of NOTCH3 promoter and BORIS ex-
pression and binding to the promoter are required for NOTCH3 upregu-
lation in T-ALL and cancer cell lines. Consistentwith this hypothesis, we
found that NOTCH3 upregulation occurs in BORIS-positive cell lines de-
rived from different cancers, showing unmethylatedNOTCH3 promoter.
To obtain information about the direct role played by BORIS in
NOTCH3 expression the highly transfectable NOTCH3- and BORIS-ex-
pressing HEK293T cell line was used. Promoter activity assays in the
condition of silencing BORIS indicate that it is directly involved in the
transcriptional upregulation of NOTCH3. Moreover, a direct analysis of
what occurred on endogenous NOTCH3 locus following modulation of
the BORIS level allowed us to establish that BORIS is directly responsible
for changes in the chromatin structure necessary for transcriptional ac-
tivation of NOTCH3. In fact, the presence of BORIS on NOTCH3 promoter
associates with an increased H3K4me3/H3K27me3 ratio.
Confirmatory finding of a role for BORIS in NOTCH3 expression was
obtained in the BORIS- and NOTCH3-negative BJ normal fibroblast
where exogenous BORIS enforced expression is sufficient to induce
NOTCH3 upregulation.
Our results are in agreement with literature data showing that BORIS
positively regulates gene expression by inducing an open chromatin
conformation [41–44]. BORIS induced alterations in the NOTCH3 pro-
moter appear highly similar to those common features typical of permis-
sive/active chromatin conformation, which have recently been reported
for Gal3st1 [43], in the physiological context of spermatogenesis, and for
the activation of cancer testis antigen TSP50 [39]. To note, genome-wide
analyses revealed that BORIS co-localizes with H3K4me3 and active PolII
Fig. 6. BORIS is a positive epigenetic regulator of NOTCH3 expression. Transient transfection of either siRNA (siRNA BORIS) or expression vectors for BORIS (Myc-BORIS) was performed in
HEK293T cells. Transfection of non-targeting siRNAs (siRNA CT) and empty overexpression vector (Vector) was performed as control. (A) Western blot analysis of cell lysates with anti-
BORIS, anti-CTCF and anti-NOTCH3 antibodies were performed to monitor endogenous protein levels. Anti-Myc antibodies were used to detect exogenous BORIS protein. Anti α-tubulin
antibodies served as control for loading differences. (B) Expression ofNOTCH3 transcript as detected by quantitative RT-PCR in HEK293T cells after transfection of either siRNA or expres-
sion vectors for BORIS. Relative levelswere calculated taking the transcriptional levels ofNOTCH3 in control transfection as 1.GUSB transcript level was used as endogenous control. Results
are means ± s.e.m. calculated from three experiments. (C) ChIP analysis of NOTCH3 promoter region for Histone H3 modifications in HEK293T cells after transfection of either siRNA or
expression vectors for BORIS. Immunoprecipitationwas performed by using specific antibodies to trimethyl lysine 4 (H3K4me3) and to trimethyl lysine 27 (H3K27me3). Normal IgGwere
used as negative control (IgG). The DNA region analyzed corresponds to the PCR amplicon indicated in Fig. 1D. *P b 0.05 compared with controls (Student's t test).
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ing that SET1A H3K4 methyltransferase is a partner of BORIS [45].
Considering that abnormal BORIS expression has been correlated
with the upregulation of proto-oncogenes in different primary tumors
[35], our next aim was to gain evidence that, in T-ALL primary samples,
where enhancedNOTCH3 gene expressionwas found [6], BORIS was co-
expressed.We found that BORIS expression correlatedwith the upregu-
lation of NOTCH3 in all inspected T-ALL patient samples.
4. Conclusions
Taken together our data suggest that BORIS aberrant expression in T-
ALL triggers NOTCH3 transcriptional activation most likely through an
epigenetic mechanism. By binding unmethylated CTCF binding sites
present onNOTCH3 promoter, BORIS favors an active chromatin confor-
mation by increasing the H3K4me3/H3K27me3 ratio (Fig. 9). Anyway,
even though our data suggest that in cancer cell lines the NOTCH3
promoter-region is co-bound simultaneously by both CTCF and BORIS,
other alternative patterns of DNA-occupancy could not be ruled out.
In fact, this region contains at least two putative target sites for the
11-zinc-finger DNA-binding domains to be independently bound either
by CTCF or by BORIS.
In conclusion, this paper not only provides insights into molecular
mechanisms underlying NOTCH3 upregulation in T-ALL, but also
suggests a novel molecular model for the action of BORIS that could be
crucial in explaining the activation of CTAs and other proto-oncogenes
in T-ALL [46].Furthermore, this study supports the opportunity to exploit BORIS
targeting for anti-cancer therapy [47–50].
5. Materials and methods
5.1. Cell culture, isolation of peripheral blood cells and patient samples
Experiments were carried out in human normal foreskin fibroblasts
expressing hTERT (BJ); T-cell acute lymphoblastic leukemia cell lines
MOLT3, SKW3 and Jurkat; breast cancer cell lines MCF7, T47D, MDA-
MB-231 and MDA-MB-453; melanoma cell lines M14 and MDA-MB-
435; colorectal cancer cell line HCT116, HCT15 and HT29; cervical can-
cer cell line HeLa; glioblastoma cell line U87; embryonic kidney cell
line HEK293T. Cell lines were maintained as subconfluent culture in
high-glucose DMEM (adherent cell culture) or RPMI (suspension cell
culture) supplementedwith 10% fetal bovine serum, 2mM L-glutamine,
50 units/ml penicillin and 50 mg/ml streptomycin. All culture solutions
were from VWR International PBI (Milan, Italy).
Peripheral blood mononuclear cells (PBMCs) were obtained from
blood of normal donors by density gradient centrifugation using
‘Lymphoprep’ solution (Axis-Shield, Dundee, UK).
For lymphocytes preparation cells were obtained as previously de-
scribed [51]. Briefly, the mature T cells, including CD8 single-positive
and CD4 single-positive, were positively selected bymagnetic cell sepa-
ration by using theMACS (magnetic cell sorter) system (Milteny Biotec,
Auburn, CA) in accordance with the manufacturer's instructions. The
purity of the isolated fractions was greater than 90%, as determined by
Fig. 7. BORIS enforced expression is sufficient to induce NOTCH3 upregulation in BORIS-negative BJ normal fibroblasts. (A) Western blot analysis of cell lysates after transfection of BORIS
expression vector (Myc-BORIS) and empty overexpression vector (Vector) as control. HEK293T samples served as positive control for BORIS and NOTCH3. Analysis was performed with
anti-BORIS, anti-NOTCH3 and anti-CTCF antibodies. Anti-Myc antibodies were used to detect exogenous BORIS protein. Antiα-tubulin antibodies served as control for loading differences.
(B) Expression of NOTCH3 transcript as detected by quantitative RT-PCR after transfection of BORIS expression vector. Relative levels were calculated taking the transcriptional levels of
NOTCH3 in control transfection as 1. GUSB transcript level was used as endogenous control. Results are means ± s.e.m. calculated from three experiments. (C) ChIP analysis of NOTCH3
promoter region for Histone H3 modifications after transfection of expression vectors for BORIS. Immunoprecipitation was performed by using specific antibodies to trimethyl lysine 4
(H3K4me3) and to trimethyl lysine 27 (H3K27me3). Normal IgG were used as negative control (IgG). The DNA region analyzed corresponds to the PCR amplicon indicated in Fig. 1D.
(D) Western blot analysis of cell lysates after transfection of BORIS expression vector and treatment with an anti-NOTCH3 IgG, known to neutralize receptor function (Ab-N3), or with
the normal control IgG (IgG). Analysis was performed with anti-Myc antibodies to detect exogenous BORIS protein and with anti-NOTCH3 antibodies. Anti α-tubulin antibodies served
as control for loading differences. (E) Expression of HES-1 transcript as detected by quantitative RT-PCR after transfection of BORIS expression vector and treatment with the anti-
NOTCH3 neutralizing IgG. Relative levels were calculated taking the transcriptional levels ofHES-1 in control transfections as 1. GUSB transcript level was used as endogenous control. Re-
sults are means ± s.e.m. calculated from three experiments. *P b 0.05 compared with controls (Student's t test).
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CD4-FITC, anti-CD8-PE, anti-CD122-FITC, and anti-CD45R/B220-PE Abs
were purchased from Pharmingen (San Diego, CA).
Eight primary T-ALL samples were obtained at the onset of disease.
All samples contained at least 70% leukemic cells.
5.2. Extraction of nucleic acids
Genomic DNA was prepared by the DNeasy tissue kit (Qiagen, Ger-
mantown, MD). Total RNA was purified by RNeasy mini kit (Qiagen,Germantown, MD). Concentration, purity and integrity of preparations
were evaluated by spectrophotometry, followed by agarose gel–
ethidium bromide electrophoresis.5.3. Reverse transcription-PCR (RT-PCR)
Total RNA (1 μg) was subjected to reverse transcription using the
SuperScript VILO cDNA synthesis kit (Life Technologies, Invitrogen,
Carlsbad, CA).
Fig. 8. Co-expression of BORIS andNOTCH3 in T-ALL primary samples. (A) Expression ofNOTCH3 transcript as detected by quantitative RT-PCR in normal blood CD4+and CD8+T-cells, in
eight cases of T-ALL, and in the leukemic cell linesMOLT3. Relative levelswere calculated taking the transcriptional level ofNOTCH3 in CD4+T-cells as 1.GUSB transcript level was used as
endogenous control. Histogram columns are labeled by the mean expression values calculated from three experiments. Error bars indicate ± s.e.m. (B) NOTCH3 promoter DNA methyl-
ation profiling as detected by COBRA assay. CD4+ T-cells and SKW3 served as positive and negative controls, respectively. The DNA region analyzed is indicated in Fig. 4B. (C and D) Ex-
pression of BORIS transcript as detected by quantitative RT-PCR in normal blood CD4+and CD8+T-cells, in eight cases of T-ALL, and in the leukemic cell linesMOLT3. Two sets of primers
encompassing 1–2 (E1–E2) and 3–4 (E3–E4) exons were used to detect all known isoforms of BORIS transcript. Detection of GUSB transcript served as endogenous control. Relative levels
were calculated taking the transcriptional levels of BORIS in MOLT3 as 1. Histogram columns are labeled by the mean expression values calculated from three experiments. Error bars in-
dicate ± s.e.m.
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real time PCR using Taq-Man gene expression assays (Life Technologies,
Applied Biosystems, Carlsbad, CA) following the manufacturer's protocol
for the comparative CT method. The amplification reaction was per-
formed using the TaqMan Universal PCR master Mix (Life Technologies,
Invitrogen, Carlsbad, CA). All samples were run in duplicate in 96-wellFig. 9. Aberrant expression of BORIS in T-ALL cells favors NOTCH3 upregulation. Figure shows a
NOTCH3 upregulation in T-ALL cells. The aberrant expression of BORIS in T-ALL cells and its recr
In fact, BORIS is required to maintain a local transcriptionally active chromatin configuration aplates on the iCycler IQ detection system (Bio-Rad, Hercules, CA). Nor-
malization was carried out using beta-glucuronidase (GUSB) as internal
control gene. TaqMan gene expression assay IDs for each set of primers
and probe were: Hs01128541_m1 (NOTCH3); Hs00902008_m1 (CTCF);
Hs00966555_g1 (BORIS E1–E2); Hs00966548_g1 (BORIS E3–E4),
Hs00172878_m1(HES1) and Hs99999908_m1 (GUSB).possible molecular mechanism underlying the association between BORIS expression and
uitment on unmethylated CTCF binding sites is permissive for the transcription ofNOTCH3.
t the NOTCH3 promoter.
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analysis (COBRA)
Bisulfite treatment of genomic DNA (1 μg) was performed by using
the EZ DNA methylation kit (Zymo Research, Irvine, CA).
For sequencing analyses the NOTCH3 promoter region was obtained
by PCR. The amplification reactions were carried out by using the
AccuPrime Taq DNA polymerase system (Life Technologies, Invitrogen,
Carlsbad, CA) with 10 pmol specific primers and 100 ng of bisulfite-
treated DNA in a final reactionmix of 25 μl. The following cycling condi-
tions were adopted. The initial denaturation at 94 °C for 2 min; 40 cy-
cles of: 94 °C for 30 s, 52 °C for 30 s, and 72 °C for 30 s. Sequencing
analysis was performed as described previously [52].
For COBRA analyses the NOTCH3 promoter region was obtained by
nested PCR.
The amplification reactions were carried out by using the AccuPrime
Taq DNA polymerase system (Life Technologies, Invitrogen, Carlsbad,
CA) with 10 pmol specific primers and 100 ng of bisulfite-treated DNA
(first amplification) or 2 μl of the first amplification in a final reaction
mix of 25 μl.
The following cycling conditions were adopted. The initial denatur-
ation at 94 °C for 2 min; 45 cycles of: 94 °C for 30 s, 50 °C (first ampli-
fication) or 52 °C (second amplification) for 30 s, and 72 °C for 40 s.
Enzyme digestion was performed with BstUI restriction endonuclease
(NewEngland Biolabs, Ipswich,MA) according tomanufacturer's proto-
col on 5 μl of the second amplification product in a final reaction mix of
20 μl. Agarose gel electrophoresis (2%) followed by ethidium bromide
staining was performed to visualize digestion products (20 μl). Primers
used for the amplifications are listed in the Supplementary Table.
5.5. Chromatin immunoprecipitation (ChIP)
ChIPwas performed as described previously [52,53]. The cross-linking
procedure was adapted for cells growing in suspension as follows.
Starting sample consisted of 1 × 107 cells from subconfluent cultures.
After centrifugation cells were resuspended in complete culture medium
added of formaldehyde (Sigma-Aldrich, St. Louis, MO) to a final concen-
tration of 1% and incubated 15 min at room temperature with gentle
shaking. To stop cross-linking reaction, cells were recovered by centrifu-
gation, resuspended in 0.125 M glycine (Sigma-Aldrich, St. Louis, MO)
in PBS and incubated for 5min at room temperature with gentle shaking.
The antibodies used for immunoprecipitations were: rabbit poly-
clonal anti-trimethyl-Histone H3 (Lys9) (Millipore, Billerica, MA); rab-
bit polyclonal anti-trimethyl-Histone H3 (Lys27) (Millipore, Billerica,
MA); mouse monoclonal anti-trimethyl-Histone H3 (Lys4) (Millipore,
Billerica, MA); rabbit polyclonal anti-dimethyl-Histone H3 (Lys4)
(Millipore, Billerica, MA); rabbit polyclonal anti-CTCF (Millipore, Biller-
ica,MA); goat polyclonal anti-BORIS (C-15) (Santa Cruz Biotechnology,
Santa Cruz, CA) and normal rabbit/mouse IgGs (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA).
End-point PCR reactions were carried out by using the AccuPrime
GC-Rich DNA polymerase system (Life Technologies, Invitrogen, Carls-
bad, CA), with 10 pmol specific primers and 5 μl of immunoprecipitated
DNA in a final reaction mix of 25 μl. The following cycling conditions
were adopted. The initial denaturation at 94 °C for 2 min; 30–45 cycles
of: 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s. Agarose gel electro-
phoresis (1.8%) followed by ethidium bromide staining was performed
to visualize PCR products (8 μl). Primers used for the amplifications are
listed in the Supplementary table.
5.6. Plasmid construction and transfection of cells
Human NOTCH3 promoter-luciferase reporter plasmids were gener-
ated using the following primers: forward, 5-ATCATGCCACTGCACTTC
AG-3, and reverse, 5-GTTCTTGCACTCCCCCTCTG-3; a 1533 bp fragment
was amplified from human genomic DNA; the amplified insert wascloned into TA-Cloning cloning vector (Life Technologies, Invitrogen,
Carlsbad, CA) and a KpnI and XhoI fragment containing the promoter
was isolated and subcloned into polylinker of the plasmid PGL3 Basic
vector (Promega, Madison, WI). This construct was denoted as full
length NOTCH3-promoter. Deletion fragments of the NOTCH3 promoter
were generated using HindIII restriction site present within the
NOTCH3-promoter which resulted in a distal fragment (−1274 to
−403 bp) and a proximal fragment (−404 to +259 bp) containing
CTCF sites.
Boris cDNA, containing the complete coding sequence (accession no.
DQ153171), was isolated by PCR amplification using the template cDNA
prepared from mouse adult testis. The following oligonucleotides were
used: 5′-CACGGAATTCAATGGCAGCCACTGAGATCTCTGTCCTT-3′sense,
5′-CCTGCTCGAGTCACTTATCCATCGTGTTGAGGAGCAT-3′ antisense. The
PCR amplified fragment was cloned in the myc-tag expression vector
pCS2-MT that inserts 6 myc tags in-frame at the carboxyl terminus of
the protein and sequenced by Eurofins MWG Operon service.
For the luciferase assays cells were transfected with Lipofectamine
2000 (Life Technologies, Invitrogen, Carlsbad, CA) according to the
manufacturer's instructions. Cells were seeded in 12-well culture plates
at a concentration of 2 × 105 cells/well and incubated for 24 h prior to
cotransfections involving luciferase reporter constructs (30 ng/well),
anti-BORIS (siGENOME SMARTpool, Thermo Fisher Scientific, 30 pmol/
well) or control siRNAs (siGENOME Non-Targeting siRNA Pool, Thermo
Fisher Scientific, 30 pmol/well). As internal control, plasmid pCMV-
beta-gal (0.5 ng/well) (Promega, Madison, WI), containing the beta-
galactosidase reporter gene, was co-transfected. Luciferase and beta-
galactosidase activities were quantitated 24 h later by the luciferase or
the β-galactosidase enzyme assay system (Promega, Madison, WI),
respectively.
For the ChIP assays 7× 105 cellswere seeded in 100×15mmculture
dishes and incubated for 24 h prior to transfection. Transfection of
siRNAs targeting BORIS and of control siRNAs (600 pmol/dish) was
performed with Lipofectamine 2000 reagent using the manufacturer's
protocol. Transfection of myc-Boris construct or empty myc-vector
(8 μg/dish) was performed with Lipofectamine Plus reagent (Life Tech-
nologies, Invitrogen, Carlsbad, CA) using the manufacturer's protocol.
After 48 h the cells were processed for ChIP, RT-PCR and for Western
blot analyses.
In the NOTCH3 activity downregulation assays, cells were seeded at
1.3 × 105 cells per well in 24-well plates 24 h prior to transfections in-
volving the myc-Boris construct or empty myc-vector (0.2 μg/well).
The transfection by Lipofectamine Plus reagent followed the manufac-
turers' protocol. At the conclusion of the transfection procedure, cells
were shifted to growth medium containing 10 μg/ml of either a sheep
polyclonal anti-NOTCH3 IgG, known to neutralize receptor function
(R&D Systems, Minneapolis, MN), or an equivalent concentration of
the normal IgG sheep control (R&D Systems,Minneapolis, MN) and cul-
tured for 48 h. Samples were than processed for Western blot and RT-
PCR analyses.
5.7. Western blot
Western blot assays were performed as described elsewhere [54].
The antibodies used were the following: mouse monoclonal anti-Myc
(9E10 clone, hybridoma-conditioned medium), mouse monoclonal
anti-BORIS (Millipore, Billerica, MA), rabbit polyclonal anti-CTCF
(Millipore, Billerica, MA); rabbit polyclonal anti-NOTCH3 (Cell Signaling
Technology, Danvers, MA) and mouse monoclonal anti-Tubulin-α
(Sigma-Aldrich, St. Louis, MO).
5.8. Statistical analysis
Statistical tests and the number of replicates performed are reported
in figure legends. Data were considered to be statistically significant if
⁎P b 0.05.
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